Described herein are compounds having Formula I or Formula II:
wherein each dashed line independently represents a saturated or unsaturated bond; R
1
and R′
1
are aryl or heteroaryl as defined herein; and R
2
and R′
2
are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula I or Formula II. The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.
[EN] INHIBITORS OF ERK NUCLEAR TRANSLOCATION<br/>[FR] INHIBITEURS DE LA TRANSLOCATION NUCLÉAIRE D'ERK
申请人:YEDA RES & DEV
公开号:WO2020115744A1
公开(公告)日:2020-06-11
Described herein are compounds having Formula (I) or Formula (II): wherein each dashed line independently represents a saturated or unsaturated bond; R1 and R'1 are aryl or heteroaryl as defined herein; and R 2 and R' 2 are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula (I) or Formula (II). The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.